Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Biomol Screen ; 9(3): 196-207, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15140381

ABSTRACT

G protein-coupled receptors (GPCRs) are a superfamily of proteins that include some of the most important drug targets in the pharmaceutical industry. Despite the success of this group of drugs, there remains a need to identify GPCR-targeted drugs with greater selectivity, to develop screening assays for validated targets, and to identify ligands for orphan receptors. To address these challenges, the authors have created a multiplexed GPCR assay that measures greater than 3000 receptor: ligand interactions in a single microplate. The multiplexed assay is generated by combining reverse transfection in a 96-well plate format with a calcium flux readout. This assay quantitatively measures receptor activation and inhibition and permits the determination of compound potency and selectivity for entire families of GPCRs in parallel. To expand the number of GPCR targets that may be screened in this system, receptors are cotransfected with plasmids encoding a promiscuous G protein, permitting the analysis of receptors that do not normally mobilize intracellular calcium upon activation. The authors demonstrate the utility of reverse transfection cell microarrays to GPCR-targeted drug discovery with examples of ligand selectivity screening against a panel of GPCRs as well as dose-dependent titrations of selected agonists and antagonists.


Subject(s)
Drug Evaluation, Preclinical/methods , Protein Array Analysis/methods , Receptors, G-Protein-Coupled/analysis , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/instrumentation , GTP-Binding Proteins/genetics , Humans , Ligands , Protein Array Analysis/instrumentation , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/antagonists & inhibitors , Receptors, G-Protein-Coupled/genetics , Transfection/methods
2.
J Virol ; 76(2): 817-28, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11752171

ABSTRACT

It is well accepted that viruses require access to specific intracellular environments in order to proliferate or, minimally, to secure future proliferative potential as latent reservoirs. Hence, identification of essential virus-cell interactions should both refine current models of virus replication and proffer alternative targets for therapeutic intervention. In the present study, we examined the activation states of mitogen-activated protein kinases (MAPKs), ERK-1/2, in primary cells susceptible to visna virus and report that virus infection induces and sustains activation of the ERK/MAPK pathway. Treatment of infected cells with PD98059, a specific inhibitor of the ERK/MAPK pathway, abolishes visna virus replication, as evidenced by extremely low levels of Gag protein expression and reverse transcriptase activity in culture supernatants. In addition, although visna virus-induced activation of MAPK is detectable within 15 min, early events of viral replication (i.e., reverse transcription, integration, and transcription) are largely unaffected by PD98059. Interestingly, further examination demonstrated that treatment with PD98059 results in decreased cytoplasmic expression of gag and env, but not rev, mRNA, highly suggestive of an ERK/MAPK-dependent defect in Rev function. In vivo analysis of ERK-1/2 activation in brains derived from visna virus-infected sheep demonstrates a strong correlation between ERK/MAPK activation and virus-associated encephalitis. Moreover, double-labeling experiments revealed that activation of MAPK occurs not only in cells classically infected by visna virus (i.e., macrophages and microglia), but also in astrocytes, cells not considered to be major targets of visna virus replication, suggesting that activation of the ERK/MAPK pathway may contribute to the virus-induced processes leading to neurodegenerative pathology.


Subject(s)
Mitogen-Activated Protein Kinases/metabolism , Virus Replication , Visna-maedi virus/physiology , Visna-maedi virus/pathogenicity , Animals , Astrocytes/enzymology , Astrocytes/virology , Brain/enzymology , Brain/pathology , Brain/virology , Butadienes/pharmacology , Cells, Cultured , Encephalitis, Viral/enzymology , Encephalitis, Viral/pathology , Encephalitis, Viral/virology , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Gene Products, env/biosynthesis , Gene Products, env/genetics , Gene Products, gag/biosynthesis , Gene Products, gag/genetics , Gene Products, rev/biosynthesis , Gene Products, rev/genetics , Goats/virology , Immunohistochemistry , MAP Kinase Kinase 1 , MAP Kinase Signaling System/drug effects , Macrophages/enzymology , Macrophages/virology , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinase Kinases/metabolism , Nitriles/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , RNA, Viral/genetics , RNA, Viral/metabolism , Sheep/virology , Virulence , Virus Replication/drug effects , Visna-maedi virus/drug effects , Visna-maedi virus/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...